EU evaluating arthritis drug to treat COVID-19
The interleukin-1 receptor antagonist may reduce cytokine storm, according to the European Medicines Agency
Europe's medicines regulator is evaluating an application to use anakinra to treat COVID-19 in adults with pneumonia who are at risk of severe respiratory failure, the agency has announced.
Anakinra is the latest potential COVID-19 treatment to be reviewed by the European Medicines Agency (EMA) as the more infectious Delta variant of the coronavirus spurs an increase in cases.
Anakinra is an interleukin-1 (IL-1) receptor antagonist and, in Australia (Kineret, Menarini) is TGA-approved for RA, systemic
